Sphere-9™ VT Ablation Catheter Clinical Evidence | Medtronic (Europe)

CAUTION: The use of the Sphere-9™ catheter for VT ablation and the associated software are investigational in Europe. This evidence has not been evaluated yet.

Features

Exclusively integrated with Affera™ mapping and ablation system

All-in-one: mapping, radiofrequency (RF) and pulsed field ablation (PFA) catheter

Wide-area focal ablation catheter

Tissue-conformable lattice tip

Pulsed field mapping to verify VT ablation targets at critical locations

Purpose and design

The Sphere-9™ Ventricular Tachycardia Early Feasibility Study (EFS) is a prospective, multicenter, nonrandomized feasibility study designed to evaluate the safety and performance of the Sphere-9™ catheter integrated with the Affera™ mapping and ablation system. The study evaluates investigational RF and PFA therapy settings for the treatment of recurrent, sustained, scar-related monomorphic VT. The study was initiated to include patients with ischemic cardiomyopathy only, and enrollment began in March 2025. The trial was expanded to included nonischemic cardiomyopathy patients in 2026. A U.S. pivotal trial (Sphere VT) was approved to begin enrollment in April 2026.

Learn more about the studies.

Trial results

VT ablation clinical outcomes^1,2

The study is a prospective EFS designed to evaluate the safety and performance of the Affera™ ablation system using the Sphere‑9™ catheter for the treatment of monomorphic VT due to prior myocardial infarction.

100%

primary
effectiveness

Acute noninducibility of the
clinically relevant VT (N = 40)

Six-month outcomes^†

0

burden
post-ablation

Median device detected VT episodes
per month post-ablation (N = 20)

65.5%

freedom from
any sustained
monomorphic VT

Interim Kaplan-Meier estimate;
follow-up ongoing for 20/40 patients

† N = device-related safety events reported in 2/40 patients.

Reddy VY, Maher TR, Higuchi K, et al. LB-525396-02: Six-month outcomes from the Sphere-9 Ventricular Tachycardia Early Feasibility Study: Dual-energy lattice-tip mapping and ablation catheter for ventricular tachycardia treatment. Presented at: HRS 2026; April 23–26, 2026; Chicago, IL.
Reddy VY, Maher TR, Higuchi K, et al. LB-525396-02: Six-month outcomes from the Sphere-9 ventricular tachycardia early feasibility study: dual-energy lattice-tip mapping and ablation catheter for ventricular tachycardia treatment. Heart Rhythm. Published online March 25, 2026. doi:10.1016/j.hrthm.2026.03.1928.

You are about to visit a website that is not operated by Medtronic.

We do not review or control the content of external sites and are not responsible for any interactions or transactions that may occur there. Any product availability and regulatory requirements on the destination site may differ depending on your location. When you continue, the terms of use and privacy statement of the external site will apply.

You are about to visit another Medtronic website.

Product availability and regulatory requirements may differ depending on your location. The destination website is governed by the laws and regulations of the country in which it operates, which may be different from those in your country. When you continue, the terms of use and privacy statement of the destination Medtronic site will apply.

First Name

Last Name

Title

STATE / PROVINCE

EMAIL

PHONE

Hospital Or Practice

Job Role

Specialty

About the latest products, technologies and services:

Yes No

About educational and clinical information (E.G. Medtronic Academy):

Yes No

Would you like to receive the Medtronic customer experience survey

Yes No

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content.

For more information, see the {link}.

You can always change your preferences or update your personal details by visiting the Preference center. {link}

First Name

Last Name

Title

STATE / PROVINCE

EMAIL

PHONE

Hospital Or Practice

Job Role

Specialty

About the latest products, technologies and services:

Yes No

About educational and clinical information (E.G. Medtronic Academy):

Yes No

Would you like to receive the Medtronic customer experience survey

Yes No

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content.

For more information, see the {link}.

You can always change your preferences or update your personal details by visiting the Preference center. {link}

First Name

Last Name

EMAIL

Hospital Or Organization

Job Role

Specialty

Confirm country/region

Before we get started, what best describes you?

OR

Confirm country/region

First Name

Last Name

EMAIL

Hospital Or Organization

Country

HOSPITAL POSTAL CODE

Job Role

Specialty

First Name

Last Name

EMAIL

PHONE

Hospital Or Organization

COUNTRY

HOSPITAL POSTAL CODE

Job Role

Specialty